Valneva (NASDAQ:VALN) Stock Price Down 3.9%

Shares of Valneva SE (NASDAQ:VALN) dropped 3.9% during trading on Friday . The company traded as low as $7.81 and last traded at $7.81. Approximately 1,758 shares changed hands during trading, a decline of 81% from the average daily volume of 9,062 shares. The stock had previously closed at $8.13.

Wall Street Analysts Forecast Growth

VALN has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st. Guggenheim cut their price target on Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, March 22nd.

Valneva Stock Performance

The stock has a 50 day moving average of $7.67 and a 200 day moving average of $9.61. The company has a quick ratio of 1.37, a current ratio of 1.65 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $526.74 million, a price-to-earnings ratio of -4.80 and a beta of 2.25.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). The company had revenue of $45.12 million during the quarter, compared to analyst estimates of $45.06 million. Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. As a group, analysts predict that Valneva SE will post 0.11 EPS for the current year.

Institutional Investors Weigh In On Valneva

A number of hedge funds have recently added to or reduced their stakes in VALN. Jane Street Group LLC increased its holdings in Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after purchasing an additional 7,664 shares in the last quarter. Bank of America Corp DE bought a new stake in Valneva in the first quarter worth approximately $858,000. Finally, UBS Group AG bought a new stake in Valneva in the second quarter worth approximately $31,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.